
Drugs like Ozempic and Wegovy have had a meteoric rise in recent years, with benefits like weight loss and help with other health issues. But according to a recent study, those benefits fade within two years of patients stopping their treatment.
According to a study published in the BMJ, data from 9,341 obese or overweight patients treated in 37 studies with any of 18 different weight-loss drugs showed that they regained about one pound on average after stopping the drugs.
The same study said they were projected to return to their pre-treatment weight in about two years.
But weight was not the only thing that was projected to return after stopping the treatment. According to the same study, health risk factors like blood pressure and cholesterol levels, which saw benefits while taking the drugs, were projected to return to their old levels within 1.4 years.
GLP-1 medications tested as well
About half of the patients studied took newer GLP-1 drugs like semaglutide, sold as Ozempic and Wegovy, as well as tirzepatide, which is sold as Mounjaro and Zepbound. According to the study, the weight regain rate was faster for these drugs, with an average of 1.8 pounds per month.
“But because people on semaglutide or tirzepatide lose more weight in the first place, they all end up returning to baseline at approximately the same time,” study senior researcher Dimitrios Koutoukidis of Oxford University told Reuters.
Weight loss drugs have shown some success
Weight loss drugs like the ones tested in the study have shown large levels of success in the United States in recent years. Back in October 2025, a survey from the Gallup National Health and Well-Being Index showed that there were an estimated 7.6 million fewer obese people in the United States compared to 2022.
In 2022, the U.S. adult obesity rate was a record-high 39.9%, while in 2025, that rate gradually declined to 37%. While the obesity rate dropped, the usage of GLP-1 drugs like Ozempic and Wegovy doubled between 2025 and 2024, according to the same study.
Contributing: Nicole Fallert, USA TODAY; Reuters
Fernando Cervantes Jr. is a trending news reporter for USA TODAY. Reach him at [email protected] and follow him on X @fern_cerv_.
This article originally appeared on USA TODAY: Here's how fast you can gain weight after ending GLP-1, per study
latest_posts
- 1
Pick Your #1 game to observe - 2
US EPA will reassess safety of herbicide paraquat, says its chief - 3
Vote In favor of Your Favored Distributed computing Administration - 4
Kissing is an ‘evolutionary conundrum.’ Scientists just mapped its unexpected origins - 5
Ancient fire discovery marks significant milestone in human history
Analysis-From 'Icarus bug' to flawed panels: Airbus counts cost of relying on single model
7 Fun Plans to Make Film Evenings Seriously Energizing (You'll Cherish #5!)
Shas threatens to oppose 2026 state budget over haredi food-voucher exclusion
US FDA panel to weigh bid to market nicotine pouches as lower-risk than cigarettes
Doctors say changes to US vaccine recommendations are confusing parents and could harm kids
NASA releases new ‘Earthset’ and eclipse images taken during historic flyby of the moon
Figure out How to Ascertain the Restitution Time frame for Your Sunlight based chargers
From Certificate to Dollars: College Majors with Extraordinary Monetary Prizes
I traveled to 13 countries in 2025. This small island nation surprised me the most.













